BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 15958811)

  • 1. Bortezomib for myeloma -- much ado about something.
    Dispenzieri A
    N Engl J Med; 2005 Jun; 352(24):2546-8. PubMed ID: 15958811
    [No Abstract]   [Full Text] [Related]  

  • 2. Bortezomib.
    Paramore A; Frantz S
    Nat Rev Drug Discov; 2003 Aug; 2(8):611-2. PubMed ID: 12908468
    [No Abstract]   [Full Text] [Related]  

  • 3. Images in clinical Medicine. Bortezomib-induced skin lesions.
    Agterof MJ; Biesma DH
    N Engl J Med; 2005 Jun; 352(24):2534. PubMed ID: 15958809
    [No Abstract]   [Full Text] [Related]  

  • 4. Bortezomib in multiple myeloma.
    Cecchi M; Caccese E; Messori A
    N Engl J Med; 2005 Sep; 353(12):1297-8; author reply 1297-8. PubMed ID: 16177258
    [No Abstract]   [Full Text] [Related]  

  • 5. Bortezomib in multiple myeloma.
    Meisler AI
    N Engl J Med; 2003 Sep; 349(13):1287-8; author reply 1287-8. PubMed ID: 14510013
    [No Abstract]   [Full Text] [Related]  

  • 6. Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
    Rodríguez-Martín M; Sáez-Rodríguez M; García-Bustínduy M; Martín-Herrera A; Noda-Cabrera A
    Dermatol Online J; 2008 Nov; 14(11):14. PubMed ID: 19094852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 2 study of bortezomib in relapsed, refractory myeloma.
    Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
    N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer research. Taking garbage in, tossing cancer out?
    Garber K
    Science; 2002 Jan; 295(5555):612-3. PubMed ID: 11809952
    [No Abstract]   [Full Text] [Related]  

  • 9. Multiple myeloma.
    Kyle RA; Rajkumar SV
    N Engl J Med; 2004 Oct; 351(18):1860-73. PubMed ID: 15509819
    [No Abstract]   [Full Text] [Related]  

  • 10. Bortezomib in multiple myeloma.
    Vandenbroucke JP; Kroep JR
    N Engl J Med; 2005 Sep; 353(12):1297-8; author reply 1297-8. PubMed ID: 16180272
    [No Abstract]   [Full Text] [Related]  

  • 11. Bortezomib increases survival of patients with relapsed multiple myeloma.
    Health News; 2005 Sep; 11(9):9. PubMed ID: 16211682
    [No Abstract]   [Full Text] [Related]  

  • 12. Hyperlipidemia in a myeloma patient after bortezomib treatment.
    Gozzetti A; Fabbri A; Defina M; Chitarrelli I; Bocchia M
    Leuk Res; 2010 Sep; 34(9):e250. PubMed ID: 20363499
    [No Abstract]   [Full Text] [Related]  

  • 13. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
    Richardson P
    Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
    Möller J; Nicklasson L; Murthy A
    J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of myeloma when high dose therapy is not possible. New drugs--alternatives for elderly patients].
    Mellstedt H; Gimsing P; Waage A
    Lakartidningen; 2011 Oct 19-25; 108(42):2090-4. PubMed ID: 22165535
    [No Abstract]   [Full Text] [Related]  

  • 16. Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks.
    Prescrire Int; 2006 Jun; 15(83):98-100. PubMed ID: 16764098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid improvement in renal function in patients with multiple myeloma and renal failure treated with bortezomib.
    Qayum A; Aleem A; Al Diab AR; Niaz F; Al Momen AK
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):63-8. PubMed ID: 20061695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib (velcade) for multiple myeloma.
    Med Lett Drugs Ther; 2003 Jul; 45(1161):57-8. PubMed ID: 12865865
    [No Abstract]   [Full Text] [Related]  

  • 19. Late onset of bortezomib-associated cutaneous reaction following herpes zoster.
    Varettoni M; Vassallo C; Borroni G; Mangiacavalli S; Zappasodi P; Rosso R; Lazzarino M; Corso A
    Ann Hematol; 2007 Apr; 86(4):301-2. PubMed ID: 17131123
    [No Abstract]   [Full Text] [Related]  

  • 20. Lenalidomide efficacy in bortezomib-resistant myeloma.
    Gozzetti A; Crupi R; Defina M; Bocchia M
    Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824907
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.